SGN-STNV is under clinical development by Seagen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGN-STNV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN-STNV is under development for the treatment of solid tumor including appendiceal adenocarcinoma, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, exocrine pancreatic adenocarcinoma, peritoneal cancer (pseudomyxoma peritonei), gastric cancer, gastroesophageal junction cancer, HER2 negative breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer and pseudomyxoma peritonei. It is administered by the intravenous route. The drug candidate is an antibody drug conjugate (ADC) with auristatin payload being developed based on the Vedotin technology platform. It acts by targeting cells expressing sialyl Thomsen-nouveau (STn). The drug candidate is developed on ADC technology.
Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas and CD30-expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
For a complete picture of SGN-STNV’s drug-specific PTSR and LoA scores, buy the report here.